Tromsø, Norway, 10[th] December 2021 - With reference to stock exchange
announcement regarding option exercise published today, 10[th] December 2021, at
12.58 CET where CEO, Jethro Holter exercised 200,000 options at a strike price
of NOK 8,00 per share, CEO Jethro Holter has sold 120.000 shares at NOK 88 per
share to cover the tax obligation and the strike price following the exercise.

Following the transaction and registration of the shares, CEO Jethro Holter has
80.564 shares and 0 options in ArcticZymes Technoloiges ASA

The information included in this announcement is such that the Company is
required to disclose in accordance with the EU Market Abuse Regulation (MAR)
section and 19 and section 5-12 of the Norwegian Securities Trading Act.

The announcement is made by CFO Børge Sørvoll, 10 December 2021, at 1955 CET.

For more information, please contact:

ArcticZymes Technologies
CFO, Børge Sørvoll        Tel: +47 95 29 01 87
                            ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.